2019 |
Dr. Daniel Zucker |
Implementation of Regulatory Requirements for Lipid based Excipients - Claims and Reality |
|
|
2018 |
Carlos Canete |
Bacteriophage therapy: an analysis of the European regulatory framework and its proposals for amendment *** |
|
|
2018 |
Lais da Silva |
Critical Assessment - Implementation of ICH Guidelines in Brazil *** |
|
|
2018 |
Sofia Dust |
Impact of China's regulatory reforms on business operations in Chinese pharmaceutical market: Perspectives and Challenges for multinational pharmaceutical companies *** |
|
|
2018 |
Zohaira El Malahi |
Maintenance of Marketing Authorizations of Medicinal Products in the MENA Region – Differences and Similarities to European Procedures *** |
|
|
2018 |
Sebastian Fischer |
The 2017 EC Report on the Paediatric Regulation - A critical analysis of stakeholder positions *** |
|
|
2018 |
Dr. Maxim Frizler |
GVP module V revision 2 a review of recommendations and main changes |
|
|
2018 |
Dr. Karin Geßele |
Regulatory Framework and Challenges for Approval of "Generic" Non-biological Complex Drugs (NBCDs) *** |
|
|
2018 |
Mareike Gleissner |
New Legal Framework for Food for Special Medical Purposes - Implications on Demarcation and Regulatory Requirements at European Level and in Germany *** |
|
|
2018 |
Dr. Florian Haberl |
IDMP - a business driver for implementation of a company wide master data management system in pharmaceutical companies |
|
|
2018 |
Hannah Hähl |
Adaptive Pathways - Challenges of a global development program for early patient access in the context of the current Health Care System and Health Technology Assessment Landscape in Europe, USA and Japan |
|
|
2018 |
Dr. Susan Heller |
Harmonisation of quality dossier following Union Referral - Challenges and points to consider with focus on sterile finished products *** |
|
|
2018 |
Dr. Claudia Heß |
Expectations of eCTD 4.0 - also a step forward for small and medium sized enterprises? *** |
|
|
2018 |
Sylvia Hinderfeld |
Labelling Requirements for Clinical Trials in the EU - Overview of current and future requirements when Regulation (EU) 536/2014 applies *** |
|
|
2018 |
Christoph Hoerth |
Change of a starting material supplier Comparison of the global post authorization change requirements with focus on the API class of synthetic peptides |
|
|
2018 |
Dr. Jutta Keil |
The representation of transdermal systems in the leading pharmacopoeias within the ICH-area and the elaboration of transdermal finished product Monographs *** |
|
|
2018 |
Maria Keyser |
Avoiding of falsified medicines: An overview of the legal situation and the impact on the pharmaceutical industry - with a focus on regulatory implementation |
|
|
2018 |
Ralf Klünder |
Besonderheiten der Arzneimittelzulassung in der Katastrophenpharmazie unter Mitbetrachtung des Geschäftsbereichs BMVg - eine Einschätzung |
|
|
2018 |
Michael Kravzow |
Regulatory considerations, opportunities and challenges for pharmaceutical companies in developing a multi-vitamin/mineral product *** |
|
|
2018 |
Sarah Kruck |
EU Herbal Monographs - chances and limitations in Regulatory Affairs |
|
|